News

A Note from Dr. Mario Raviglione


10 Feb 2010
by Working Group

Dr. Mario Raviglione
Dr. Mario Raviglione

Never before in the recent history of tuberculosis research have we been so close to seeing the arrival of new drug breakthroughs that could help reshape the course of TB care and control in a direct and positive way. WHO is fully supportive of the impressive efforts and energies that have been invested by the scientific community over the last decade in the search for new and more effective anti-TB drugs.

The contribution to TB control from this research community will have a far-reaching impact on the lives of millions in the future, and we all hope that the continued challenges in developing new drugs can be overcome swiftly as the need is urgent.

We welcome the launch of this website and look forward to accessing regular up-to-date information about the progress and achievements of the New Drug working group and helping to share this information with the world at large.

— Dr. Mario Raviglione, Director of WHO Stop TB Department

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...